Optimizing drug regimens in cancer chemotherapy by an efficacy-toxicity mathematical model

Computers and Biomedical Research

Volumn 33, Issue 3, 2000, Pages 211-226

  Iliadis, Athanassios ^a   Barbolosi, Dominique ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CANCER; CANCER CELL DESTRUCTION; CANCER CHEMOTHERAPY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; LEUKOPENIA; MAINTENANCE THERAPY; MATHEMATICAL MODEL; PRIORITY JOURNAL;

EID: 0033933808     PISSN: 00104809     EISSN: None     Source Type: Journal    
DOI: 10.1006/cbmr.2000.1540     Document Type: Article

References (39)

1. Swan G. W., Vincent T. L. Optimal control analysis in the chemotherapy of IgG multiple myeloma. Bull. Math. Biol. 39:1977;317.
2. Swan G. W. Applications of Optimal Control Theory in Biomedicine. 1984;Dekker, New York.
3. Swan G. W. Role of optimal control theory in cancer chemotherapy. Math. Biosci. 101:1990;237.
4. Holford N. H. G., Sheiner L. B. Understanding the dose-effect relationship: Clinical application of pharmacokinetic-pharmacodynamic models. Clin. Pharmacokin. 6:1981;429.
5. Holford N. H. G., Sheiner L. B. Kinetics of pharmacologic response. Pharmacol Ther. 16:1982;143.
6. Bezwoda W. R. High-dose chemotherapy with hematopoietic rescue in breast cancer: From theory to practice. Cancer Chemother. Pharmacol. 40:1997;S79.
7. Peters W. P., Dansey R. New concepts in the treatment of breast cancer using high-dose chemotherapy. Cancer Chemother. Pharmacol. 40:1997;S88.
8. Ratain M. J., Schilsky R. L., Conley B. A., Egorin M. J. Pharmacodynamics in cancer therapy. J. Clin. Oncol. 8:1990;1739.
9. Devita V. T. Principles of chemotherapy. DeVita V. T., Hellman S., Rosenberg S. A. Principles and Practice in Oncology. 1985;257-285 Lippincott, Philadelphia.
10. Seber G. A. F., Wild C. J. Nonlinear Regression Analysis. 1989;Wiley, New York.
11. Kahn M. G., Fagan L. M., Sheiner L. B. Combining physiologic models and symbolic methods to interpret time-varying patient data. Methods Inform. Med. 30:1991;167.
12. Martin R. B. Optimal control drug scheduling of cancer chemotherapy. Automatica. 28:1992;1113.
13. Sundareshan M. K., Fundakowski R. S. Periodic optimization of a class of bilinear systems with application to control of cell proliferation and cancer therapy. IEEE Trans. Systems, Man, Cybernet. SMC-15:1985;102.
14. Iliadis A., Bruno R., Cano J. P. Dynamical dosage regimen calculations in linear pharmacokinetics. Comput. Biomed. Res. 21:1988;203.
15. Murray J. M. Some optimal control problems in cancer chemotherapy with a toxicity limit. Math. Biosci. 100:1990;49.
16. Murray J. M. Optimal control for a cancer chemotherapy problem with general growth and loss functions. Math. Biosci. 13:1990);437.
17. Stewart C. F. Use of etoposide in patients with organ dysfunction: Pharmacokinetic and pharmacodynamic considerations. Cancer Chemother. Pharmacol. 34:1994;S76.
18. Joel S. P., Shah R., Slevin M. L. Etoposide dosage and pharmacodynamics. Cancer Chemother. Pharmacol. 34:1994;S69.
19. Karlsson M. O., Port R. E., Ratain M. J., Sheiner L. B. A population model for the leukopenic effect of etoposide. Clin. Pharmacol. Ther. 57:1995;325.
20. Clark, P. I, Slevin, M. L, Joel, S. P, Osborne, R. J, Talbot, D. I, Johnson, P. W. M, Reznek, R, Masud, T, Gregory, W, and, Wrigley, P. F. M. A randomized trial of two etoposide schedules in small-lung cancer: The influence of pharmacokinetics on efficacy and toxicity, J. Clin. Oncol. 12, 1427, (, 1994, ).
21. Stewart C. F., Arbuck S. G., Fleming R. A., Evans W. E. Relation of systemic exposure to unbound etoposide and hematologic toxicity. Clin. Pharmacol. Ther. 50:1991;385.
22. Slevin M. L., Clark P. I., Joel S. P. A randomnized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J. Clin. Oncol. 7:1989;1333.
23. Ratain M. J., Schilsky R. L., Choi K. E., Guarnieri C., Grimmer D., Vogelzang N. J., Senekjian E., Liebner M. A. Adaptive control of etoposide administration: Impact of interpatient pharmacodynamic variability. Clin. Pharmacol. Ther. 45:1989;226.
24. Thompson D. S., Hainsworth J. D., Hande K. R., Holzmer M. C., Greco F. A. Prolonged administration of low-dose, infusional etoposide in patients with etoposide-sensitive neoplasms: A phase I-II study. J. Clin. Oncol. 11:1993;1322.
25. Saijo N. Chemotherapy: The more the better? Overview. Cancer Chemother. Pharmacol. 40:1997;S100.
26. Collins J. M., Zaharko D. S., Dedrick R. L., Chabner B. A. Potential roles for preclinical pharmacology in phase I clinical trials. Cancer Treat. Rep. 70:1986;73.
27. Berry B. W., Erlichman C. Clinical pharmacology of anticancer drugs. Schilsky R. L., Milano G. A., Ratain M. J. Principles of Antineoplastic Drug Development and Pharmacology. 1996;75-122 Dekker, New York.
28. Mick R., Ratain M. J. Statistical approaches to pharmacodynamic modeling: Motivations, methods, and misperceptions. Cancer Chemother. Pharmacol. 33:1993;1.
29. Coldman A. J., Goldie J. H. A model for the resistance of tumor cells to cancer chemotherapeutic agents. Math. Biosci. 65:1983;291.
30. Gordon M. S. Hematopoietic growth factors and cancer chemotherapy. Schilsky R. L., Milano G. A., Ratain M. J. Principles of Antineoplastic Drug Development and Pharmacology. 1996;241-262 Dekker, New York.
31. Gabrilove J., Jakubowki A., Scher H., Sternberg C., Wong G., Grous J., Yacoda A., Fain K., Moore M., Clarkson B., Oettgen H., Alton K., Welte K., Souza L. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N. Engl. J. Med. 318:1988;1414.
32. Mick R., Ratain M. J. Modeling interpatient pharmacodynamic variability of etoposide. J. Natl. Cancer Inst. 83:1991;1560.
33. Ratain M. J., Mick R., Schilsky R. L., Vozelzang N. J., Berezin F. Pharmacologically based dosing of etoposide: A means of safely increasing dose intensity. J. Clin. Oncol. 9:1991;1480.
34. Papoulis A. Signal Analysis. 1987;McGraw-Hill.
35. Eykhoff P. System Identification. 1974;Wiley, London.
36. Ruffer, D. F.Implementation and properties of a method for the identification of nonlinear continuous time models. In "7th Triennial World Conference of Automatic Control" (A. Nuomi, Ed.), pp. 1919-1926. Finland, 1978.
37. Bellman R., Cooke K. L. Differential-Difference Equations. 1963;Academic Press, New York.
38. Barbolosi D., Iliadis A. Pharmacokinetic modeling of drugs subject to enterohepatic circulation. Aiache J. M., Hirtz J. Third European Congress of Biopharmaceutics and Pharmacokinetics. 1987;179-187 University Press, Freiburg.
39. MATLAB, High-performance numeric computation and visualization software. Release 4.2c.1, Natick MA, The Math Works, 1993.